These genes are strongly associated with cancer risk and may have clear clinical actionability, supporting the goal that each addition to the panel provides meaningful insights for patient care. The ...

Get here Class 12th Biology paper pattern along with marking scheme and marks distribution for important topics.

Genetic testing has had a shift in the past ten years, as it has left medical laboratories and entered living rooms.

Myriad Genetics (MYGN) stock is downgraded from a "Buy" to "Hold" due to flat Q3 2025 earnings and limited near-term revenue ...

SALT LAKE CITY, Nov. 10, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced MyRisk®Hereditary Cancer Test —the gold ...

Myriad Genetics (MYGN) announced MyRisk Hereditary Cancer Test-the gold standard in germline testing-has been expanded to include genes referenced ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research studies highlighting advancements in oncology and ...

Millions struggle with depression and anxiety, often enduring long waits for effective treatment. Scientists in Sweden, ...

Genetic testing company Myriad Genetics (NASDAQ:MYGN) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 3 ...

Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, will exhibit its latest scientific research and findings in genetic testing at The National Society of Genetic ...

Get key insights from Myriad Genetics’ Q3 2025 earnings call, growth strategies, financial outlook, and new product launches.

Myriad Genetics, Inc., a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis ...